Clinical Trial

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-05-02; most recent amendment 2026-07-15.
Status change: Not Yet Recruiting → Recruiting 2025-08-19
Trial Details
NCT Number NCT06966024
Lead Sponsor Deciphera Pharmaceuticals, LLC
Conditions Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
Enrollment 60 participants
Start Date 2025-08-27
Primary Completion 2029-02 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-16